We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+2.68%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$2.63B
AUM Growth
+$312M
Cap. Flow
+$315M
Cap. Flow %
11.96%
Top 10 Hldgs %
49.1%
Holding
89
New
29
Increased
24
Reduced
12
Closed
15

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$69M
2
BIIB icon
Biogen
BIIB
+$42.3M
3
AXSM icon
Axsome Therapeutics
AXSM
+$34.6M
4
ALC icon
Alcon
ALC
+$31.7M
5
INSM icon
Insmed
INSM
+$29.1M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.6M
2
ABBV icon
AbbVie
ABBV
+$72.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$71.9M
4
AZN icon
AstraZeneca
AZN
+$69.4M
5
LLY icon
Eli Lilly
LLY
+$66.3M

Sector Composition

Rank Sector Weight
1 Healthcare 75.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37B
$310M 11.78%
1,550,280
– –
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.3B
$149M 5.66%
+600,000
New +$155M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$134M 5.1%
+1,050,000
New +$131M
BMY icon
4
Bristol-Myers Squibb
BMY
$128B
$121M 4.58%
1,988,721
+475,727
+31% +$27.7M
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$16B
$113M 4.3%
598,327
-361,533
-38% -$63.2M
VERA icon
6
Vera Therapeutics
VERA
$2.53B
$112M 4.27%
2,793,987
– –
UTHR icon
7
United Therapeutics
UTHR
$26.3B
$94.9M 3.61%
160,070
+2,429
+2% +$1.21M
AZN icon
8
AstraZeneca
AZN
$263B
$89.9M 3.42%
456,031
-360,136
-44% -$69.4M
QQQ icon
9
PUT
Invesco QQQ Trust
QQQ
$449B
$86.6M 3.29%
+150,000
New +$91.1M
COGT icon
10
Cogent Biosciences
COGT
$6.91B
$81.4M 3.09%
2,113,551
+139,926
+7% +$5.17M
IBB icon
11
PUT
iShares Biotechnology ETF
IBB
$9.44B
$80.2M 3.05%
+475,000
New +$81.2M
RARE icon
12
Ultragenyx Pharmaceutical
RARE
$2.65B
$65.9M 2.5%
3,145,888
+3,062,588
+3,677% +$69M
RAPP
13
Rapport Therapeutics
RAPP
$2.01B
$59.6M 2.26%
1,904,408
– –
INSM icon
14
Insmed
INSM
$22.7B
$56.6M 2.15%
346,075
+189,274
+121% +$29.1M
ALC icon
15
Alcon
ALC
$32.8B
$55M 2.09%
729,972
+397,452
+120% +$31.7M
SUPN icon
16
Supernus Pharmaceuticals
SUPN
$2.73B
$49.3M 1.87%
954,309
+401,214
+73% +$20.4M
UTHR icon
17
PUT
United Therapeutics
UTHR
$26.3B
$47.6M 1.81%
+80,300
New +$40M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$11.6B
$44.2M 1.68%
781,982
+84,849
+12% +$4.95M
BIIB icon
19
Biogen
BIIB
$29.5B
$42.1M 1.6%
+229,521
New +$42.3M
CELC icon
20
Celcuity
CELC
$4.01B
$41.8M 1.59%
366,175
+66,758
+22% +$7.28M
BIOA
21
BioAge Labs
BIOA
$928M
$40.1M 1.52%
2,293,788
– –
RYTM icon
22
Rhythm Pharmaceuticals
RYTM
$7.28B
$39.1M 1.49%
450,096
+178,702
+66% +$17.4M
AVBP icon
23
ArriVent BioPharma
AVBP
$1.4B
$39.1M 1.49%
1,696,752
– –
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.54B
$37.7M 1.43%
1,131,786
+246,665
+28% +$8.28M
IMNM icon
25
Immunome
IMNM
$2.56B
$37.2M 1.41%
1,701,904
+83,427
+5% +$1.86M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2026 Portfolio in Review

As of Q1 2026, Sofinnova Investments held 89 positions worth $2.63B, up 13% from $2.32B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sofinnova Investments deployed $315M of net new capital in Q1 2026, opening 29 new positions and adding to 24 existing holdings. Its largest new stake was Biogen: 229,521 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was AstraZeneca, an estimated $69.4M trimmed.

  • Sofinnova Investments's largest Q1 2026 buy was Biogen: 229,521 shares worth $42.1M.
  • Sofinnova Investments added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $69M increase.
  • Sofinnova Investments's biggest Q1 2026 reduction was AstraZeneca, cutting an estimated $69.4M.
  • Sofinnova Investments fully exited Vertex Pharmaceuticals in Q1 2026, selling an estimated $74.6M.
  • Sofinnova Investments's ten largest holdings make up 49% of its $2.63B portfolio in Q1 2026.
  • Sofinnova Investments opened 29 new positions and closed 15 in Q1 2026.
  • Sofinnova Investments's portfolio value rose 13% quarter-over-quarter to $2.63B.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.